Brief: Genexine granted FDA orphan drug designation for GX-H9 in growth hormone deficiency
16/11/2016 13:00
Nov 16 (Reuters) - Genexine Inc 095700.KQ
* Genexine granted FDA orphan drug designation for GX-H9 in
growth hormone deficiency
Source text for Eikon: urn:newsml:reuters.com:*:nBw7TlX4Ca
Further company coverage: 095700.KQ
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Genexine
See all newsBrief: Genexine Announces Merger With EPD Biotherapeutics
Brief: Genexine To Invest 29 Billion Won As Part Of Consortium In Building New Research And Development Centre In Seoul, South Koreａ
Brief: Genexine To Divest 19 Billion Won Worth Of Shares In Ajinomoto Genexine Co
Brief: Genexine Receives Fast Track Designation From Korean Health Authority For Vaccine For Advanced Cervical Cancer
Indonesia in talks with WHO to become global vaccine hub: minister